Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance

Leukemia

Volumn 25, Issue 3, 2011, Pages 387-399

  Thiel, A ^a   Beier, M ^a   Ingenhag, D ^a   Servan, K ^a   Hein, M ^a   Moeller, V ^a   Betz, B ^a   Hildebrandt, B ^a   Evers, C ^a,b   Germing, U ^a   Royer Pokora, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

aCGH; myelodysplastic syndromes; normal karyotype; prognosis

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; TRANSCRIPTION FACTOR RUNX1;

ALLELIC IMBALANCE; ARTICLE; CHROMOSOME 21Q; CHROMOSOME 4Q; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA MICROARRAY; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; SURVIVAL; TUMOR SUPPRESSOR GENE;

EID: 79952452217     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.293     Document Type: Article

References (38)

1. Brunning RS, Orazi A, Germing U, LeBeau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lympoid Tissues, 4th edn. IARC Press: Lyon, France, 2008, pp 88-93. .
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199. . (Pubitemid 12073508)
3. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510. . (Pubitemid 47315575)
4. Paulsson K, Heidenblad M, Strömbeck B, Staaf J, Jönsson G, Borg A et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 2006; 20: 840-846. .
5. O'Keefe CL, Tiu R, Gondek LP, Powers J, Theil KS, Kalaycio M et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp Hematol 2007; 35: 240-251. . (Pubitemid 46135810)
6. Starczynowski DT, Vercauteren S, Telenius A, Sung S, Tohyama K, Brooks-Wilson A et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008; 112: 3412-3424. .
7. Evers C, Beier M, Poelitz A, Hildebrandt B, Servan K, Drechsler M et al. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Genes Chromosomes Cancer 2007; 46: 1119-1128. . (Pubitemid 47614546)
8. Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365-3373. . (Pubitemid 350106331)
9. Gondek LP, Haddad AS, Keefe CL, Tiu R, Wlodarski MW, Sekeres MA et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 2007; 35: 1728-1738. . (Pubitemid 47633771)
10. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 2009; 23: 1605-1613. .
11. Trolet J, Hupé P, Huon I, Lebigot I, Decraene C, Delattre O et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 2009; 50: 2572-2580. .
12. Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800. .
13. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147. .
14. Wagner LA, Christensen CJ, Dunn DM, Spangrude GJ, Georgelas A, Kelley L et al. EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression. Blood 2007; 109: 5191-5198. . (Pubitemid 46890536)
15. Del Mare S, Salah Z, Aqeilan RI. WWOX: its genomics, partners, and functions. J Cell Biochem 2009; 108: 737-745. .
16. van Barjesteh Waalwijk Doorn-Khosrovani S, Erpelinck C, van Putten WLJ, Valk PJM, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837-845. . (Pubitemid 36139348)
17. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, Ghosh J et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 2009; 29: 9210-9218. .
18. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 2009; 113: 6403-6410. .
19. Langemeijer SMC, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842. .
20. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301. .
21. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923-3932. .
22. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285-3291. .
23. Liu TX, Becker MW, Jelinek J, Wu W, Deng M, Mikhalkevich N et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13: 78-83. . (Pubitemid 46067389)
24. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110: 719-726. . (Pubitemid 47105411)
25. Xie H, Hu Z, Chyna B, Horrigan SK, Westbrook CA. Human mortalin (HSPA9): a candidate for the myeloid leukemia tumor suppressor gene on 5q31. Leukemia 2000; 14: 2128-2134. . (Pubitemid 32042252)
26. Ohtsuka R, Abe Y, Fujii T, Yamamoto M, Nishimura J, Takayanagi R et al. Mortalin is a novel mediator of erythropoietin signaling. Eur J Haematol 2007; 79: 114-125. . (Pubitemid 47063253)
27. Hu Z, Gomes I, Horrigan SK, Kravarusic J, Mar B, Arbieva Z et al. A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene 2001; 20: 6946-6954. . (Pubitemid 33052184)
28. Graubert TA, Payton MA, Shao J, Walgren RA, Monahan RS, Frater JL et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS ONE 2009; 4: e4583. .
29. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-12979. .
30. Fischer K, Fröhling S, Scherer SW, McAllister Brown J, Scholl C, Stilgenbauer S et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 1997; 89: 2036-2041. .
31. Tosi S, Scherer SW, Giudici G, Czepulkowski B, Biondi A, Kearney L. Delineation of multiple deleted regions in 7q in myeloid disorders. Genes Chromosomes Cancer 1999; 25: 384-392. . (Pubitemid 29326146)
32. Gondek LP, Tiu R, O0Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008; 111: 1534-1542. . (Pubitemid 351213443)
33. Hofmann W, Tong X, Ajioka RS, Kushner JP, Koeffler HP. Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. Blood 2002; 100: 1099-1100. . (Pubitemid 34832652)
34. Wang Z, Miura N, Bonelli A, Mole P, Carlesso N, Olson DP et al. Receptor tyrosine kinase, EphB4 (HTK), accelerates differentiation of select human hematopoietic cells. Blood 2002; 99: 2740-2747. . (Pubitemid 34525360)
35. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Barlogie B et al. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 2009; 114: 1803-1812. .
36. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002; 2: 502-513. . (Pubitemid 37328932)
37. Heinrichs S, Li C, Look AT. SNP array analysis in hematologic malignancies: avoiding false discoveries. Blood 2010; 115: 4157-4161. .
38. Praulich I, Tauscher M, Göhring G, Glaser S, Hofmann W, Feurstein S et al. Clonal heterogeneity in childhood myelodysplastic syndromesFchallenge for the detection of chromosomal imbalances by array-CGH. Genes Chromosomes Cancer 2010; 49: 885-900.